Valo Therapeutics Ltd

Our CSO Sari Pesonen will be participating as an expert speaker at the 8th Annual Oncolytic Virotherapy Summit, from 12-14 December in Boston, USA! 5.15-5.45 | 14 December | “PeptiCRAd - A Novel Cancer Immunotherapy Approach Targeting Multiple Tumour Antigens” Sari will be presenting PeptiCRAd, our next generation #cancer #immunotherapy platform that targets multiple #tumor antigens simultaneously, increasing the likelihood of immune recognition and supercharging patient response against a wide range of cancer types. Join the talk, and contact us to meet Sari there to learn more about how PeptiCRAd has the potential to reinvent immunotherapy in #oncology, enabling it to be personalized to every cancer patient. 🔗 Join the 8th Annual Oncolytic Virotherapy Summit: https://lnkd.in/dudemFeT 📧 Meet Sari at the event: info@valotx.com Hanson Wade Group

We’re proud to announce we have received regulatory approval to expand our Phase I trial into two subtypes of sarcoma: synovial and myxoid round cell sarcoma. The approval from Germany’s Paul Ehrlich Institute extends the inclusion criteria to four cancer types in our Phase I first-in-human PeptiCRAd-1 with Pembrolizumab trial: sarcoma, melanoma, triple negative breast cancer, and non-small cell lung cancer. PeptiCRAd-1 combines the immune system activating potency of an oncolytic virus and the power of anti-tumor cytotoxic T-cells. It is the only oncolytic virus therapy that targets tumor antigens in this way. Our approach to reinventing #immunotherapy in #oncology, enables it to be personalized to every cancer patient with PeptiCRAd - a highly specific, immunogenic, and rapidly adaptable platform for the treatment of #cancer. Sarcomas are cancers that develop in the bones and soft tissues, with around 12,000 cases in the US each year. 🔗 Read our press release: https://lnkd.in/eQkpCaRR 🔬 Find out more on our novel, adaptable, immunotherapy platforms for cancer: www.valotx.com #biotech #pharma

Our CSO Sari Pesonen is speaking at Biomarkers Europe 2023, from 14-15 November in Berlin! 📅09:25 – 09:50 | 15 November | Track 1: "PeptiCRAd – An Oncolytic Fusion Immunotherapy Approach For Solid Tumors In Combination With Checkpoint Blockade" Learn how our lead asset PeptiCRAd-1 delivers a highly specific, immunogenic and rapidly adaptable platform for the treatment of #cancer. Combining immune activating oncolytic adenovirus and a tumor-specific peptide vaccine, it provides a flexible immunotherapy platform focused on generating systemic cytotoxic T cell responses and modulating #tumor microenvironment (TME). Join to hear more about our approach to reinventing #immunotherapy in #oncology, enabling it to be personalized to every cancer patient. 🔗 Join Biomarkers Europe 2023: https://lnkd.in/eU9v93kK 📧 Meet Sari at the event: info@valotx.com Oxford Global #BioTech #Innovation #ClinicalTrials

We are pleased to announce we have opened our third #ClinicalTrial site, at the University Hospital in Tübingen, Germany, at the Eberhard Karls University of Tuebingen’s Gene and RNA Therapy Centre (GRTC), one of the country’s top clinical virotherapy centers.  At the GRTC, Prof. Ulrich M. Lauer’s group is focusing on preclinical and clinical research on oncolytic virotherapy. GRTC joins #cancer centers at Krankenhaus Nordwest in Frankfurt, and at National Center for Tumor Diseases (NCT) Heidelberg. This supports study enrollment into the Phase I study with lead product PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus 1) which is being administered together with checkpoint inhibitor pembrolizumab in patients with melanoma, triple negative breast cancer or non-small cell lung cancer. PeptiCRAd-1 combines an #oncolytic adenovirus and tumor-specific peptides for the generation of a strong systemic cytotoxic T-cell responses against multiple tumor antigens. Find out more on our novel, adaptable, #immunotherapy platform for cancer: www.valotx.com Universitätsklinikum Tübingen #BioTech #Innovation #clinicaltrials

🤝 We are pleased to announce we are the first #biotech company in Europe to install and use the Bruker Corporation’s new timsTOF Ultra mass spectrometer instrument with unparalleled sensitivity, which will enable rapid identification of Tumor Antigens in conjunction with our own PeptiCHIP technology! Tumor neoantigens are expressed uniquely by #cancer cells and their presence can trigger an efficient immune response against the tumor, and using Bruker’s top-of-the line platform increases allows us to identify thousands of antigens from each PeptiCHIP processed tiny tumor sample with unparalleled speed, sensitivity, and robustness. 🔗 Read the full release: https://lnkd.in/e-QwuzhY 🚀 Find out more on our novel, adaptable, immunotherapy platforms for cancer: www.valotx.com Otto Kari, Paul G Higham #Innovation #ImmunoTherapy

Join us at the Cancer Research Institute (CRI) International Cancer Immunotherapy Conference from September 20 – 23 in Milan, where Charlotta Backman and Lukasz Kuryk are looking forward to connecting with the community on advances in cancer research, #cancer #immunotherapy! This year’s theme is ‘Translating Science into Survival’, so schedule a meeting at info@valotx.com to hear how our innovative approach based on the selective use of #oncolytic viruses with disease-specific peptides can transform treatment for cancer patients. 🔗Visit valotx.com to find out more on our novel, adaptable, immunotherapy platforms for cancer. 📅 Link to the event: https://lnkd.in/dGNwfqH European Network for Cancer Immunotherapy, American Association for Cancer Research #CICON23 #Innovation #BioTech

Hear our CSO Sari Pesonen on a Lumanity live webinar panel discussion. Sari will be talking with Andrew Allen Jens Bjørheim Lauren Wood and Livija Deban on “Helping Make Tumors Hot: Have Cancer Vaccines Come in from the Cold?” Moderated by Jeff Bockman & Viraj Parekh, PhD. The panel will discuss cancer vaccines, pre-clinical requirements for attracting pharma interest, clinical development strategy for optimizing chances of achieving POC/POR, and ways to best position a cancer vaccine program/platform for investment or partnerships. Tune in on June 27 from 11:00-12:15pm EST. Register today at https://buff.ly/3IE4IQk Contact us at info(at)valotx.com to find out more about #immunotherapy platforms for #cancer #biotech #pharma #oncology

We’ve joined forced with Texcell in a #research #collaboration evaluating immune responses to our lead asset PeptiCRAd-1 in a Phase 1 clinical study in #cancer: http://bit.ly/3J9vNer This #partnership will provide valuable information about the immunological mechanism of action of PeptiCRAd-1, as we reinvent #immunotherapy to make it more powerful. #oncology #biotech #CRO #clinicaltrials

Hear from our CSO Sari Pesonen at the Precision Medicine Forum this month. Sari will be presenting about our proprietary PeptiCRAd #technology which enables the binding of disease-targeting #peptides to the surface of oncolytic vectors, promoting an enhanced #TCell driven #immune response to destroy the targeted tumour. Contact us at info(at)valotx.com to find out more about #immunotherapy platforms for #cancer #biotech #pharma #OncologyForum

Great news for our lead product PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus 1) which has been used to treat the first patient in our Phase Ib, first-in-human #ClinicalTrial for patients with #melanoma, triple negative breast cancer or non-small cell lung cancer: https://lnkd.in/dxZ4GaCT Thank you to Prof Elke Jäger and her team at Krankenhaus Nordwest GmbH in Frankfurt and Prof. Guy Ungerechts and his team at National Center for Tumor Diseases (NCT) Heidelberg for their work in helping us reach this milestone! PeptiCRAd-1 combines the #immune system activating potency of an #oncolytic #virus and the power of anti-tumor cytotoxic T-cells.